SRF inhibitors reduce prostate cancer cell proliferation through cell cycle arrest in an isogenic model of castrate-resistant prostate cancer

References

• Mitsiades N, Kaochar S. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. Endocr Relat Cancer. 2021;28(8):T19–T38. doi: 10.1530/ERC-21-0098
   PubMed Web of Science ®Google Scholar
• Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–460. doi: 10.1016/S0140-6736(21)02437-5
   PubMed Web of Science ®Google Scholar
• Saxby H, Boussios S, Mikropoulos C. Androgen receptor gene pathway upregulation and radiation resistance in oligometastatic prostate cancer. Int J Mol Sci. 2022;23(9):23(9. doi: 10.3390/ijms23094786
   PubMed Web of Science ®Google Scholar
• Heemers HV, Regan KM, Dehm SM, et al. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res. 2007;67(21):10592–10599. doi: 10.1158/0008-5472.CAN-07-1917
   PubMed Web of Science ®Google Scholar
• Foley C, Mitsiades N. Moving beyond the Androgen Receptor (AR): targeting AR-Interacting proteins to treat prostate cancer. Horm Cancer. 2016;7(2):84–103. doi: 10.1007/s12672-015-0239-9
   PubMed Web of Science ®Google Scholar
• Heemers HV. Androgen receptor and prostate cancer: new insights in an old target translate into novel therapeutic strategies. Curr Drug Targets. 2013;14(4):399–400. doi: 10.2174/1389450111314040001
   PubMed Web of Science ®Google Scholar
• Prencipe M, Madden SF, O’Neill A, et al. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target? Prostate. 2013;73(7):743–753. doi: 10.1002/pros.22618
   PubMed Web of Science ®Google Scholar
• Verone AR, Duncan K, Godoy A, et al. Androgen-responsive serum response factor target genes regulate prostate cancer cell migration. Carcinogenesis. 2013;34(8):1737–1746. doi: 10.1093/carcin/bgt126
   PubMed Web of Science ®Google Scholar
• Prencipe M, Fabre A, Murphy TB, et al. Role of serum response factor expression in prostate cancer biochemical recurrence. Prostate. 2018;78(10):724–730. doi: 10.1002/pros.23516
   PubMed Web of Science ®Google Scholar
• Prencipe M, O’Neill A, O’Hurley G, et al. Relationship between serum response factor and androgen receptor in prostate cancer. Prostate. 2015;75(15):1704–1717. doi: 10.1002/pros.23051
   PubMed Web of Science ®Google Scholar
• Azam H, Pierro L, Reina M, et al. Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer. Expert Opin Ther Targets. 2022;26(2):155–169. doi: 10.1080/14728222.2022.2032652
   PubMed Web of Science ®Google Scholar
• Venkadakrishnan VB, DePriest AD, Kumari S, et al. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene. 2019;38(23):4496–4511. doi: 10.1038/s41388-019-0732-7
   PubMed Web of Science ®Google Scholar
• Watson RW, Azam H, Aura C, et al. Inhibition of serum response factor improves response to enzalutamide in prostate cancer. Cancers (Basel). 2020;12(12):12(12. doi: 10.3390/cancers12123540
   Web of Science ®Google Scholar
• Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81(2):242–251. doi: 10.1038/sj.bjc.6690684
   PubMed Web of Science ®Google Scholar
• Evelyn CR, Wade SM, Wang Q, et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007;6(8):2249–2260. doi: 10.1158/1535-7163.MCT-06-0782
   PubMed Web of Science ®Google Scholar
• Watanabe B, Minami S, Ishida H, et al. Stereospecific inhibitory effects of CCG-1423 on the cellular events mediated by myocardin-related transcription factor a. PLoS One. 2015;10(8):e0136242. doi: 10.1371/journal.pone.0136242
   PubMed Web of Science ®Google Scholar
• Lisabeth EM, Kahl D, Gopallawa I, et al. Identification of pirin as a molecular target of the CCG-1423/CCG-203971 series of antifibrotic and antimetastatic compounds. ACS Pharmacol Transl Sci. 2019;2(2):92–100. doi: 10.1021/acsptsci.8b00048
   PubMedGoogle Scholar
• Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010;19(3):427–436. doi: 10.1517/13543781003598862
   PubMed Web of Science ®Google Scholar
• Collins C, Carducci MA, Eisenberger MA, et al. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther. 2007;6(9):1356–1363. doi: 10.4161/cbt.6.9.4541
   Web of Science ®Google Scholar
• Brown PA, Kairalla JA, Hilden JM, et al. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: children’s Oncology Group trial AALL0631. Leukemia. 2021;35(5):1279–1290. doi: 10.1038/s41375-021-01177-6
   PubMed Web of Science ®Google Scholar
• O’Neill AJ, Prencipe M, Dowling C, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011;10(1):126. doi: 10.1186/1476-4598-10-126
   PubMedGoogle Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi: 10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Arsenian S, Weinhold B, Oelgeschläger M, et al. Serum response factor is essential for mesoderm formation during mouse embryogenesis. Embo J. 1998;17(21):6289–6299. doi: 10.1093/emboj/17.21.6289
   PubMed Web of Science ®Google Scholar
• Evelyn CR, Lisabeth E, Wade S, et al. Small-molecule inhibition of Rho/MKL/SRF transcription in prostate cancer cells: modulation of cell cycle, ER Stress, and metastasis gene networks. Microarrays (Basel). 2016;5(2):5(2. doi: 10.3390/microarrays5020013
   PubMedGoogle Scholar
• Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6(1):e001. doi: 10.1621/nrs.06001
   PubMedGoogle Scholar
• Farra R, Dapas B, Pozzato G, et al. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. Biochimie. 2010;92(5):455–463. doi: 10.1016/j.biochi.2010.01.007
   PubMed Web of Science ®Google Scholar
• He X, XU H, ZHAO M, et al. Serum response factor is overexpressed in esophageal squamous cell carcinoma and promotes Eca-109 cell proliferation and invasion. Oncol Lett. 2013;5(3):819–824. doi: 10.3892/ol.2013.1120
   PubMed Web of Science ®Google Scholar
• Valdagni R, Van Poppel H, Aitchison M, et al. Prostate cancer unit initiative in Europe: a consensus on standards of care. Ann Oncol. 2015;26:66–66. doi: 10.1093/annonc/mdv341.45
   Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038. doi: 10.1056/NEJMoa1315815
   PubMed Web of Science ®Google Scholar
• Kahl DJ, Hutchings KM, Lisabeth EM, et al. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids: a highly potent new class of inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-mediated gene transcription as potential antifibrotic agents for scleroderma. J Med Chem. 2019;62(9):4350–4369. doi: 10.1021/acs.jmedchem.8b01772
   PubMed Web of Science ®Google Scholar
• Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003;35(6):577–593. doi: 10.1016/S0022-2828(03)00110-X
   PubMed Web of Science ®Google Scholar
• Miano JM, Long X, Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol. 2007;292(1):C70–81. doi: 10.1152/ajpcell.00386.2006
   PubMed Web of Science ®Google Scholar
• Gualdrini F, Esnault C, Horswell S, et al. SRF co-factors control the balance between cell proliferation and contractility. Molecular Cell. 2016;64(6):1048–1061. doi: 10.1016/j.molcel.2016.10.016
   PubMed Web of Science ®Google Scholar
• Metzger E . A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. Embo J. 2003;22(2):270–280. doi: 10.1093/emboj/cdg023
   PubMed Web of Science ®Google Scholar
• Ioannidou E, Moschetta M, Shah S, et al. Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets. Int J Mol Sci. 2021;22(18):9926. doi: 10.3390/ijms22189926
   PubMed Web of Science ®Google Scholar
• Lim JTE, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells (vol 102, 5156, 2005). Proc Natl Acad Sci USA. 2005;102(24):8786–8787. doi: 10.1073/pnas.0501203102
   Web of Science ®Google Scholar
• Yamamoto A, Hashimoto Y, Kohri K, et al. Cyclin E as a coactivator of the androgen receptor. J Cell Bio. 2000;150(4):873–879. doi: 10.1083/jcb.150.4.873
   PubMed Web of Science ®Google Scholar
• Shah S, Rachmat R, Enyioma S, et al. BRCA mutations in prostate cancer: assessment, implications and treatment considerations. Int J Mol Sci. 2021;22(23):12628. doi: 10.3390/ijms222312628
   PubMed Web of Science ®Google Scholar
• Hutchings KM, Lisabeth EM, Rajeswaran W, et al. Pharmacokinetic optimitzation of CCG-203971: novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017;27(8):1744–1749. doi: 10.1016/j.bmcl.2017.02.070
   PubMed Web of Science ®Google Scholar
• Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat Rev Cancer. 2019;19(8):439–453. doi: 10.1038/s41568-019-0156-2
   PubMed Web of Science ®Google Scholar
• Wyld L, Bellantuono I, Tchkonia T, et al. Senescence and cancer: a review of clinical implications of senescence and senotherapies. Cancers (Basel). 2020;12(8):12(8. doi: 10.3390/cancers12082134
   PubMed Web of Science ®Google Scholar
• Prensner JR, Rubin MA, Wei JT, et al. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127rv3. doi: 10.1126/scitranslmed.3003180
   PubMed Web of Science ®Google Scholar